Tremfya™ (guselkumab) – New drug approval
July 13, 2017 – Janssen Biotech announced the FDA approval of Tremfya (guselkumab), for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Download PDF
